Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Image: Yahoo Finance
ad slot · in-content video 16:9
Coverage
More coverage
Technology news, aggregated

Image: Yahoo Finance
More coverage